Oncología Traslacional
ONCTRAS
University Hospital Heidelberg
Heidelberg, AlemaniaPublicacions en col·laboració amb investigadors/es de University Hospital Heidelberg (4)
2020
-
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
The Lancet Oncology, Vol. 21, Núm. 4, pp. 519-530
2019
-
Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2416-2428
2016
-
Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-Expressing platinum-resistant ovarian Cancer (PENELOPE)
Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2516-2525
-
Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial
International Journal of Gynecological Cancer, Vol. 26, Núm. 5, pp. 898-905